

## Eylea®, Eylea® HD (aflibercept) Injection

When requesting Eylea®, Eylea® HD (aflibercept), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial uses and meet the specific coverage guidelines for the covered indication.

### FDA-Approved Indications

Eylea is indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Retinopathy of prematurity (ROP)

Eylea HD is indicated for the treatment of patients with:

- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Neovascular (wet) age-related macular degeneration (AMD)

### Approved Off-Label Compendial Uses

#### Eylea

- Other neovascular ophthalmic conditions (e.g., neovascular glaucoma, sickle cell neovascularization, choroidal neovascular conditions)

### Coverage Guidelines

#### Eylea

For all approved indications the individual must meet the following criteria for approval:

- Eylea is administered by or under the supervision of an ophthalmologist.

#### Eylea HD

For all approved indications the individual must meet the following criteria for approval:

- Eylea is administered by or under the supervision of an ophthalmologist.

**Approval duration (Eylea and Eylea HD): 12 months**

### Dosing Recommendations

## **Eylea**

### **Neovascular (Wet) Age-Related Macular Degeneration (AMD)**

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg via intravitreal injection once every 8 weeks.

### **Macular Edema Following Retinal Vein Occlusion (RVO)**

The recommended dose is 2 mg administered by intravitreal injection once every 4 weeks.

### **Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)**

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for the first 5 injections followed by 2 mg via intravitreal injection once every 8 weeks.

### **Retinopathy of Prematurity (ROP)**

The recommended dose is 0.4 mg administered by intravitreal injection. The treatment interval between doses injected into the same eye should be at least 10 days.

## **Eylea HD**

### **Neovascular (Wet) Age-related Macular Degeneration (AMD)**

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for the first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 16 weeks.

### **Diabetic Macular Edema**

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for the first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 16 weeks.

### **Diabetic Retinopathy**

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 12 weeks.

## **References**

1. Eylea® injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; December 2023.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.
6. Eylea®HD intravitreal injection [prescribing information]. Tarrytown, NY: Regeneron; December 2023.